SEP 21, 2016
Macula Society Reviews Ocriplasmin for Vitreomacular Traction
ASRS 2016
05:00
Retina/Vitreous
In this interview from ASRS 2016, Dr. Jennifer I. Lim discusses a retrospective study from the Macula Society showing that outcomes with ocriplasmin for vitreomacular traction (VMT) are better than reported in the clinical trial, the MIVI-TRUST study. Dr. Lim and colleagues showed that approximately 45% of patients treated with ocriplasmin alone achieved VMT release by 1 month, with results sustained throughout 1 year of follow-up. Approximately 35% of macular holes were closed at 1 month, and 40% achieved closure at 1 year. A subanalysis also showed good success in patients with macular holes larger than 400 microns.